Novel IDH1-Targeted Glioma Therapies.

Abstract:

:Mutations in the isocitrate dehydrogenase (IDH) 1 gene are commonly found in human glioma, with the majority of low-grade gliomas harboring a recurrent point mutation (IDH1 R132H). Mutant IDH reveals an altered enzymatic activity leading to the synthesis of 2-hydroxyglutarate, which has been implicated in epigenetic mechanisms of oncogenesis. Nevertheless, it is unclear exactly how IDH mutations drive glioma initiation and progression, and it is also not clear why tumors with this mutation generally have a better prognosis than IDH wild-type tumors. Recognition of the high frequency of IDH mutations in glioma [and also in other malignancies, including acute myeloid leukemia (AML) and cholangiocarcinoma] have led to the development of a number of targeted agents that can inhibit these enzymes. Enasidenib and ivosidenib have both gained regulatory approval for IDH mutant AML. Both agents are still in early clinical phases for glioma therapy, as are a number of additional candidates (including AG-881, BAY1436032, and DS1001). A marked clinical problem in the development of these agents is overcoming the blood-brain barrier. An alternative approach to target the IDH1 mutation is by the induction of synthetic lethality with compounds that target poly (ADP-ribose) polymerase (PARP), glutamine metabolism, and the Bcl-2 family of proteins. We conclude that within the last decade, several approaches have been devised to therapeutically target the IDH1 mutation, and that, potentially, both IDH1 inhibitors and synthetic lethal approaches might be relevant for future therapies.

journal_name

CNS Drugs

journal_title

CNS drugs

authors

Karpel-Massler G,Nguyen TTT,Shang E,Siegelin MD

doi

10.1007/s40263-019-00684-6

subject

Has Abstract

pub_date

2019-12-01 00:00:00

pages

1155-1166

issue

12

eissn

1172-7047

issn

1179-1934

pii

10.1007/s40263-019-00684-6

journal_volume

33

pub_type

杂志文章
  • Maternal Anti-Fetal Brain IgG Autoantibodies and Autism Spectrum Disorder: Current Knowledge and its Implications for Potential Therapeutics.

    abstract::Several studies have found a correlation between the presence of circulating maternal autoantibodies and neuronal dysfunction in the neonate. Specifically, maternal anti-brain autoantibodies, which may access the fetal compartment during gestation, have been identified as one risk factor for developing autism spectrum...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-015-0279-2

    authors: Fox-Edmiston E,Van de Water J

    更新日期:2015-09-01 00:00:00

  • Management of psychiatric comorbidity in anorexia nervosa and bulimia nervosa.

    abstract::The eating disorders anorexia nervosa and bulimia nervosa present with comorbidity in a number of important areas, including depression, bipolar disorder, anxiety disorders (obsessive-compulsive disorder, panic disorder, social anxiety disorder and other phobias, and post-traumatic stress disorder) and substance abuse...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200620080-00004

    authors: Woodside BD,Staab R

    更新日期:2006-01-01 00:00:00

  • VMAT2 Inhibitors in Neuropsychiatric Disorders.

    abstract::The basal ganglia and dopaminergic pathways play a central role in hyperkinetic movement disorders. Vesicular monoamine transporter 2 (VMAT2) inhibitors, which deplete dopamine at presynaptic striatal nerve terminals, are a class of drugs that have long been used to treat hyperkinetic movement disorders, but have rece...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-018-0580-y

    authors: Tarakad A,Jimenez-Shahed J

    更新日期:2018-12-01 00:00:00

  • Guide to anaesthetic selection for electroconvulsive therapy.

    abstract::Electroconvulsive therapy (ECT) is used in the treatment of severe psychiatric disorders. It involves the induction of a seizure for therapeutic purposes by the administration of a variable-frequency electrical stimulus via electrodes applied to the scalp. The original application of ECT in non-anaesthetised patients ...

    journal_title:CNS drugs

    pub_type: 指南,杂志文章,实务指引,评审

    doi:10.2165/00023210-200519090-00002

    authors: Wagner KJ,Möllenberg O,Rentrop M,Werner C,Kochs EF

    更新日期:2005-01-01 00:00:00

  • Methylene Blue in the Treatment of Neuropsychiatric Disorders.

    abstract::Methylene blue is a long-established drug with complex pharmacology and multiple clinical indications. Its diverse mechanisms of action are most likely responsible for the large variety of its clinical effects. Of interest to psychiatrists, methylene blue has antidepressant, anxiolytic, and neuroprotective properties ...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-019-00641-3

    authors: Alda M

    更新日期:2019-08-01 00:00:00

  • Lower IQ is associated with decreased clinical response to atomoxetine in children and adolescents with attention-deficit hyperactivity disorder.

    abstract:OBJECTIVES:Atomoxetine is commonly used to treat attention-deficit hyperactivity disorder (ADHD) in children with a broad range of cognitive abilities. We examined the association between level of cognitive functioning as determined by IQ and clinical response during treatment with atomoxetine. METHODS:The records of ...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.2165/11590450-000000000-00000

    authors: Mazzone L,Reale L,Mannino V,Cocuzza M,Vitiello B

    更新日期:2011-06-01 00:00:00

  • Neuroprotection in multiple sclerosis: a therapeutic approach.

    abstract::Multiple sclerosis (MS) is a demyelinating disease of the central nervous system that is pathologically characterized by inflammatory demyelination and neurodegeneration. Axonal damage, along with neuronal loss, occurs from disease onset and may lead to progressive and permanent disability. In contrast with the inflam...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-013-0093-7

    authors: Maghzi AH,Minagar A,Waubant E

    更新日期:2013-10-01 00:00:00

  • Tianeptine: a review of its use in depressive disorders.

    abstract:UNLABELLED:Tianeptine is an antidepressant agent with a novel neurochemical profile. It increases serotonin (5-hydroxytryptamine; 5-HT) uptake in the brain (in contrast with most antidepressant agents) and reduces stress-induced atrophy of neuronal dendrites. Like the selective serotonin reuptake inhibitors (SSRIs) and...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200115030-00006

    authors: Wagstaff AJ,Ormrod D,Spencer CM

    更新日期:2001-01-01 00:00:00

  • Post Hoc Analysis of Potential Predictors of Response to Atomoxetine for the Treatment of Adults with Attention-Deficit/Hyperactivity Disorder using an Integrated Database.

    abstract:BACKGROUND:Responses to atomoxetine vary for individual patients with attention-deficit/hyperactivity disorder (ADHD). However, we do not know whether any factors can be used to reliably predict how individuals with ADHD will respond to treatment. OBJECTIVE:Our objective was to evaluate background variables that facil...

    journal_title:CNS drugs

    pub_type: 临床试验,杂志文章

    doi:10.1007/s40263-016-0323-x

    authors: Bushe C,Sobanski E,Coghill D,Berggren L,De Bruyckere K,Leppämäki S

    更新日期:2016-04-01 00:00:00

  • Pregabalin: as adjunctive treatment of partial seizures.

    abstract::Pregabalin, the pharmacologically active S-enantiomer of 3-aminomethyl-5-methylhexanoic acid, possesses anticonvulsant activity. Pregabalin binds with high affinity and specificity to voltage-gated calcium channel alpha(2)-delta proteins. The putative mechanism of action of the drug is reduced excitatory neurotransmit...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200519030-00007

    authors: Warner G,Figgitt DP

    更新日期:2005-01-01 00:00:00

  • Calcium Channel Antagonists as Disease-Modifying Therapy for Parkinson's Disease: Therapeutic Rationale and Current Status.

    abstract::Parkinson's disease is a disabling hypokinetic neurological movement disorder in which the aetiology is unknown in the majority of cases. Current pharmacological treatments, though effective at restoring movement, are only symptomatic and do nothing to slow disease progression. Electrophysiological, epidemiological an...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-016-0393-9

    authors: Swart T,Hurley MJ

    更新日期:2016-12-01 00:00:00

  • Pharmacoeconomic spotlight on varenicline as an aid to smoking cessation.

    abstract::Varenicline (Chantix, Champix) is an orally administered alpha4beta2 nicotinic acetylcholine receptor partial agonist that is indicated as an aid to smoking cessation. Varenicline was an effective aid to smoking cessation and was generally well tolerated in clinical trials, although more data are needed regarding the ...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11204710-000000000-00000

    authors: Keating GM,Lyseng-Williamson KA

    更新日期:2010-09-01 00:00:00

  • Bipolar depression: management options.

    abstract::Bipolar depression is the predominant abnormal mood state in bipolar disorder. However, despite the key pertinence of this phase of the condition, the focus of research and indeed of clinical interest in the management of bipolar disorder has been mainly on mania. Bipolar depression has been largely neglected, and ear...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200317010-00002

    authors: Malhi GS,Mitchell PB,Salim S

    更新日期:2003-01-01 00:00:00

  • Overview of Current Drug Delivery Methods Across the Blood-Brain Barrier for the Treatment of Primary Brain Tumors.

    abstract::Existing drug delivery methods have not led to a significant increase in survival for patients with malignant primary brain tumors. While the combination of conventional therapies consisting of surgery, radiotherapy, and chemotherapy has improved survival for some types of brain tumors (e.g., WNT medulloblastoma), oth...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-020-00766-w

    authors: Haumann R,Videira JC,Kaspers GJL,van Vuurden DG,Hulleman E

    更新日期:2020-11-01 00:00:00

  • Weight regain after discontinuation of topiramate treatment in patients with migraine: a prospective observational study.

    abstract:PURPOSE:To monitor weight regain after therapy discontinuation in patients with migraine experiencing weight loss during topiramate (TPM) treatment. METHODS:Patients with migraine without aura were enrolled in this observational prospective study. Weight, body mass index (BMI), waist circumference, systolic and diasto...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.1007/s40263-015-0229-z

    authors: Verrotti A,Parisi P,Agostinelli S,Loiacono G,Marra F,Coppola G,Pisani LR,Gorgone G,Striano P,Pisani F,Belcastro V

    更新日期:2015-02-01 00:00:00

  • Acetyl-L-carnitine in HIV-associated antiretroviral toxic neuropathy.

    abstract::Nucleoside analogue reverse transcriptase inhibitors (NRTIs), used as part of highly active antiretroviral therapy for the treatment of HIV and AIDS, disrupt neuronal mitochondrial DNA synthesis, resulting in antiretroviral toxic neuropathy (ATN). Acetyl-L-carnitine (ALC) enhances neurotrophic support of sensory neuro...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200721001-00004

    authors: Youle M

    更新日期:2007-01-01 00:00:00

  • Safety and efficacy of intravenous lacosamide for adjunctive treatment of refractory status epilepticus: a comparative cohort study.

    abstract:BACKGROUND:Refractory status epilepticus (RSE) is an emergency with high mortality requiring neurointensive care. Treatment paradigms include first-generation antiepileptic drugs (AEDs) and anesthetics. Lacosamide (LCM) is a new AED, holding promise as a potent treatment option for RSE. High-level evidence regarding sa...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.1007/s40263-013-0049-y

    authors: Sutter R,Marsch S,Rüegg S

    更新日期:2013-04-01 00:00:00

  • Long-Term Treatment of Restless Legs Syndrome (RLS): An Approach to Management of Worsening Symptoms, Loss of Efficacy, and Augmentation.

    abstract::Restless legs syndrome (RLS) is a common, frequently chronic, sensorimotor neurological disorder characterized by nocturnal leg dysesthesias and an irresistible urge to move the legs, usually resulting in sleep disturbance. Dopaminergic agonists, alpha-2-delta calcium-channel ligands, and opioids have all demonstrated...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-015-0250-2

    authors: Mackie S,Winkelman JW

    更新日期:2015-05-01 00:00:00

  • Pharmacological interventions for the treatment of smokeless tobacco use.

    abstract::Smokeless tobacco (SLT) is used in a variety of forms throughout the world. Long-term SLT use is associated with adverse health consequences. Effective pharmacotherapies are needed to treat SLT users who want to achieve tobacco abstinence. In the current review, we discuss the pharmacological interventions identified ...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11598450-000000000-00000

    authors: Ebbert JO,Fagerstrom K

    更新日期:2012-01-01 00:00:00

  • Efficacy and tolerability of zolmitriptan oral tablet in the acute treatment of menstrual migraine.

    abstract:OBJECTIVE:To determine the efficacy and tolerability of zolmitriptan 2.5 mg oral tablet as an acute treatment for menstrual migraine attacks. METHODS:This was a two-phase, multicentre, randomised, double-blind, placebo-controlled, parallel-group outpatient study (Phase I is reported here). The study was conducted at 2...

    journal_title:CNS drugs

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.2165/00023210-200620120-00005

    authors: Tuchman M,Hee A,Emeribe U,Silberstein S

    更新日期:2006-01-01 00:00:00

  • Pharmacotherapy of malignant astrocytomas of children and adults: current strategies and future trends.

    abstract::This article reviews the conceptual progression in the pharmacological therapy of malignant astrocytoma (MA) over the past decade, and its future trends. It is a selective rather than an exhaustive inventory of literature citations. The experience of the Brain Tumour Cooperative Group (BTCG) and earlier phase III tria...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200115090-00005

    authors: Jennings MT,Iyengar S

    更新日期:2001-01-01 00:00:00

  • Potential of Glial Cell Modulators in the Management of Substance Use Disorders.

    abstract::The pervasive and devastating nature of substance use disorders underlies the need for the continued development of novel pharmacotherapies. We now know that glia play a much greater role in neuronal processes than once believed.  The various types of glial cells (e.g., astrocytes, microglial, oligodendrocytes) partic...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.1007/s40263-020-00721-9

    authors: Jones JD

    更新日期:2020-07-01 00:00:00

  • Treating depression in children and adolescents: what options now?

    abstract::There have been significant developments in the understanding of depression in children and adolescents in the past few years, including an increased recognition that significant depressive illness occurs in this patient group. Pharmacological and psychotherapeutic treatments are used to manage depression in children ...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200620010-00001

    authors: Varley CK

    更新日期:2006-01-01 00:00:00

  • Spotlight on levetiracetam in epilepsy.

    abstract::Levetiracetam (Keppra®, E Keppra®) is an established second-generation antiepileptic drug (AED). Worldwide, levetiracetam is most commonly approved as adjunctive treatment of partial-onset seizures with or without secondary generalization; other approved indications include monotherapy treatment of partial-onset seizu...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11208340-000000000-00000

    authors: Lyseng-Williamson KA

    更新日期:2011-10-01 00:00:00

  • Efficacy of olanzapine and ziprasidone for the treatment of schizophrenia: a systematic review.

    abstract::It is difficult to determine the relative efficacy of atypical antipsychotics for the treatment of schizophrenia, based on the available literature. The purpose of this article is to review and compare the efficacy of two atypical antipsychotics: olanzapine and ziprasidone.This review focused on randomised trials in w...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200519060-00003

    authors: Matza LS,Baker TM,Revicki DA

    更新日期:2005-01-01 00:00:00

  • Novel Thrombolytics for Acute Ischemic Stroke: Challenges and Opportunities.

    abstract::Progress in finding a better alternative to alteplase has been slow. Tenecteplase and desmoteplase have better pharmacological profiles compared with alteplase, but definite clinical evidence of their superiority is lacking. The two major phase III studies that have tested the efficacy and safety of desmoteplase in is...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.1007/s40263-015-0307-2

    authors: Logallo N,Kvistad CE,Nacu A,Thomassen L

    更新日期:2016-02-01 00:00:00

  • Therapeutic Potential of Ursolic Acid to Manage Neurodegenerative and Psychiatric Diseases.

    abstract::Ursolic acid is a pentacyclic triterpenoid found in several plants. Despite its initial use as a pharmacologically inactive emulsifier in pharmaceutical, cosmetic and food industries, several biological activities have been reported for this compound so far, including anti-tumoural, anti-diabetic, cardioprotective and...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-017-0474-4

    authors: Ramos-Hryb AB,Pazini FL,Kaster MP,Rodrigues ALS

    更新日期:2017-12-01 00:00:00

  • New formulations of stimulants for attention-deficit hyperactivity disorder: therapeutic potential.

    abstract::New formulations of stimulant medications for the treatment of attention-deficit hyperactivity disorder (ADHD) have been an important focus for pharmaceutical industry research and development over the past decade. In this article, we review and assess the therapeutic potential of five new stimulant formulations (one ...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200418140-00005

    authors: Connor DF,Steingard RJ

    更新日期:2004-01-01 00:00:00

  • Presynaptic dopaminergic function: implications for understanding treatment response in psychosis.

    abstract::All current antipsychotic drugs block dopamine (DA) receptors, but the nature of the DA dysfunction in schizophrenia has not been clear. However, consistent evidence now shows that presynaptic dopaminergic function is altered in schizophrenia, specifically in terms of increased DA synthesis capacity, baseline synaptic...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-014-0177-z

    authors: Bonoldi I,Howes OD

    更新日期:2014-07-01 00:00:00

  • Association Between Statin Use and Depressive Symptoms in a Large Community-Dwelling Older Population Living in Australia and the USA: A Cross-Sectional Study.

    abstract:BACKGROUND:Statin use has been frequently associated with depressive symptoms in an older population. However, the nature of this association is uncertain in the literature. In this study, we aimed to investigate the association of statin intake and the prevalence of depressive symptoms in healthy community-dwelling ol...

    journal_title:CNS drugs

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s40263-019-00633-3

    authors: Agustini B,Mohebbi M,Woods RL,McNeil JJ,Nelson MR,Shah RC,Murray AM,Ernst ME,Reid CM,Tonkin A,Lockery JE,Berk M,ASPREE Investigator Group.

    更新日期:2019-07-01 00:00:00